ArticleBritish journal of cancer2013
Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Insights into targeting LKB1 in tumorigenesis.Genes & diseases · 2025Review
- Sodium butyrate induces autophagy in colorectal cancer cells through LKB1/AMPK signaling.Journal of physiology and biochemistry · 2019Article
- Metabolomics and Metabolic Reprogramming in Kidney Cancer.Seminars in nephrology · 2018Review
- Methylation ofOncology letters · 2017Article
- Metabolic reprogramming in clear cell renal cell carcinoma.Nature reviews. Nephrology · 2017Review
- Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma.Oncology letters · 2017Article
- Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?Therapeutic advances in urology · 2016Review
- Deletion of Lkb1 in Renal Tubular Epithelial Cells Leads to CKD by Altering Metabolism.Journal of the American Society of Nephrology : JASN · 2016Article
- Rewiring cell polarity signaling in cancer.Oncogene · 2015Review
- The role of death-associated protein 3 in apoptosis, anoikis and human cancer.Cancer cell international · 2015Article
- Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression.Clinical & experimental metastasis · 2014Article
- Endoplasmic reticulum protein ERp46 in renal cell carcinoma.PloS one · 2014Article
- Mitochondrial and performance adaptations to exercise training in mice lacking skeletal muscle LKB1.American journal of physiology. Endocrinology and metabolism · 2013Article
- Potential applications for biguanides in oncology.The Journal of clinical investigation · 2013 · on this mapReview
- CD44 and CD74: The promising candidates for molecular targeted therapy in oral squamous cell carcinoma.Dental research journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEvidence suggests that dysregulation of energy-sensing pathways closely associates with renal cell carcinoma (RCC) development. The metabolic regulation is largely controlled by 5'-AMP activated protein kinase (AMPK) which is activated through phosphorylation by LKB1.
methodsThe expression of LKB1 was determined by reverse transcription-PCR using 10 clinical clear cell RCC (ccRCC) samples and their adjacent normal renal parenchyma, and by immunohistochemical staining of two tissue microarrays containing 201 ccRCC and 26 normal kidney samples. Expression of LKB1 was knocked down in human ccRCC 786-O cells (shLKB1) and compared with cells expressing scrambled control shRNA (shControl). AMPK signalling, proliferation, invasion, and VEGF secretion was measured. The cells were subcutaneously injected into mice to determine tumour growth in vivo.
resultsAt the protein and transcript levels, a significant reduction in LKB1 expression in tumour compared with normal tissue was found. In vitro, knockdown of LKB1 resulted in reduced AMPK signalling and increased cellular proliferation, invasion, and VEGF secretion compared with shControl cells. In vivo, growth of shLKB1 ccRCC xenografts in nude mice was significantly increased compared with shControl xenografts.
conclusionCollectively, our results suggest that LKB1 acts as a tumour suppressor in most sporadic cases of ccRCC and that underexpression of LKB1 is a common event in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.